ANGPTL3 and metabolic dysfunction-associated steatotic liver disease: Our results indicated that the VHH-Fc fusion protein could block ANGPTL3-mediated suppression of LPL activity in vitro, reduce serum lipid levels and ameliorated hepatic lipid accumulation and liver injury in NAFLD mice (Fig. 1).